Background: Patients with airways disease have been demonstrated to be at risk of osteoporosis, and this is likely to be multifactorial. Our aim was to identify patients with low bone mineral density (BMD) using a screening program, and then evaluate the benefit of daily alendronate. Method: Subjects with hip or lumbar spine baseline T-scores <-2.5, or Z-score < -1.0 commenced on alendronate/calcium (10 mg/600 mg day) or placebo/calcium, in a double blind randomized controlled trial. BMD by dual emission X-ray absorptiometry (lumbar vertebrae 2-4, neck of femur, total femur) was repeated after 12 months, with adverse events recorded. Results: 145 subjects (74 male, 71 female, mean age 67, median FEV, 1.0 litres = 43% of predicted) were enrolled; 66 alendronate/calcium, 79 placebo/calcium with 24 and 26 withdrawals, respectively. Per protocol but not intention to treat analysis of covariance demonstrated statistically significant improvements in T and Z scores for lumbar spine bone mineral density (P = 0.035, P = 0.040), with no improvement demonstrated at the hip. Conclusions: Improvement in bone mineral density has been demonstrated at the lumbar spine, but not hip, by per protocol analysis, with daily alendronate, at 12 months. Chronic Respiratory Disease 2004; 1: 131-137
Introduction
Osteoporotic fractures have substantial public health significance, with high economic costs, high 12 month post hip fracture mortality, and loss of independence including nursing home placement.1-2 Systematic review of studies of bone densities and fractures demonstrate a high risk of osteoporosis in subjects with asthma and chronic obstructive airways disease (COAD),3 with bone mineral density (BMD) reductions of up to 29%.4 Such reductions have important fracture implications, as a BMD reduction of the order of one standard deviation (approximately 10%) is associated with a 2.6-fold increase in the risk of hip fracture. 5 Apart from the effect of corticosteroids on bone3 other potential contributory factors to osteoporosis in this patient group have been reported. Relationships between asthma, reductions in physical activity and, in turn, reduced BMD have been described. 6 8 Poor lung function,9 smokingl0 and potential for reduced dietary calcium due to 'milk makes mucus' beliefs," may expose people with ainvays disease to particular risk of osteoporosis.
In postmnenopausal women, medications such as alendronate have been demonstrated to increase BMD and reduce fractures. '2-14 Alendronate has also been shown to have benefit in people on oral corticosteroids,'5 however the effects of such therapy in people specifically with airways disease have not been reported.
Our aim was to evaluate the effects of daily alendronate upon BMD in patients with airways disease who also have low BMD.
Methods

Sampling frame
Subjects with airways disease (asthma and/or COAD) were recruited in Adelaide, South Australia, from three metropolitan teaching hospitals and a general practice (Adelaide Western Division of General Practice). Patients recruited from hospitals were identified on the basis of ICD-9 or ICD-10 discharge codes as having either asthma, chronic bronchitis, emphysema or COAD. Outpatients were also recruited from respiratory clinics within the three hospitals. Relevant institutional ethics committee approvals were obtained from all institutions.
Recruitment and randomization
Subjects were contacted by mailed letter and provided with an information sheet or were contacted by their doctor. As a means of identifying a high risk population, researchers completed a prescreening checklist using information obtained through audit of medical records. This checklist was based upon the available literature, and was designed to have a low threshold for inclusion. Subjects were required to achieve a score of at least five to be eligible for inclusion in the study. Two points were allocated for the following risk factors: >2 courses of prednisolone in the last two years, forced expiratory volume in one second (FEVy) < 50% predicted, any respiratory admission in the last five years, severely limited exercise tolerance (unable to walk > 100 m unaided), being a woman aged over 50 and sustaining a bone fracture after the age of 40. One point was allocated for each of the following risk factors: inhaled corticosteroid dose > 1.5 mg daily for at least two years, FEVy of <75 % predicted, smoker for >40 pack years, limited exercise tolerance (able to walk between 100 and 300 m unaided) and a BMI of < 18.
Patients who were eligible using the prescreening checklist ( Figure 1 ), underwent BMD testing. Bone 
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Randomized controlled trial of alendronate BJ Smith et al. 133 density was measured for the neck offemur, total femur and lumbar spine (L2-4) using dual energy X-ray absorptiometry [(DXA) Lunar DPXplu densitometer].16 BMD measurements were transformed into Z scores, (standard deviations above or below the mean compared to matched age and gender) as well as T scores (compared to young adult mean for their gender). Subjects found to have T scores <-2.5, or Z score <-1.0 at hip or lumbar spine were eligible for inclusion in the trial.
Subjects were randomized according to a computer generated list of random numbers. Participants and investigators were blinded to the treatment until the study ended.
Exclusion criteria
Patients for whom alendronate was contraindicated were excluded from the study (if subjects unable to sit upright for more that 30 minutes, a history of known renal disease or who suffered symptoms of dysphagia, dyspepsia, use of proton pump inhibitors or alcohol dependence) or history of bilateral hip replacements.
Intervention
Patient received alendronate sodium equivalent to 10 mg/day alendronic acid (Fosamax, Merck, Sharp and Dohme, USA) and calcium 600 mg/day (Caltrate, Wyeth, Australia) or placebo and calcium given at three monthly clinic visits. Participants continued any usual drug treatment and any new drugs that were advised during routine care.
Outcome factors
BMD was repeated after 12 months. Patients were assessed at three monthly intervals, either at clinic visits or via a telephone consultation. Patients were asked whether they had experienced any adverse events over the previous three month period. Adverse events included difficulty swallowing and oesophagitis, nausea and vomiting, chest pain and rash. As a means of measuring compliance, participants were asked to return their study medication container at each visit, together with any unused tablets, for counting.
Sample size
Heijckmann et al. 17 found a 21% improvement in T score for lumbar spine in women with severe menopausal osteoporosis. Based on this, a sample size of 52 in each group would have 80% power to detect a difference between mean lumbar spine T scores at 12 months of -2.50 for the placebo group and -2.00 for the alendronate group assuming a common standard deviation of 0.90, and using a two group t-test with a 0.05 two sided significance level. Allowing for a 25% withdrawal rate, a sample size of 70 was required in each group.
Statistical analysis
We included all participants randomized to the treatment or placebo group in the analyses, according to intention to treat. In a secondary per protocol analysis, we repeated the analysis on only those patients not withdrawing from the trial. Tests for differences between groups for categorical variables were undertaken by Exact chi-squared test or Fisher's Exact test. Unadjusted tests for differences in means between groups were undertaken by independent sample Student's t-test for nonnally distributed variables, and Exact Mann-Whitney U-test for other variables. Tests for differences in BMD between groups at 12 months after adjusting for baseline values were undertaken by analysis of covariance. All analyses were undertaken using SPSS 11.5 for Windows.
Results
Baseline
One hundred and forty-five patients entered the study (66 alendronate, 79 placebo). Figure 1 demonstrates sampling frame, sample and follow up at 12 months. The average age of the patients was 67 years (SD 8.6 years) and patients in the two study groups had similar mean age, height and weight. Median FEV1 (% predicted) was also similar in the two groups with 44.0% for placebo and 41.5% for alendronate. Table 1 shows other patient characteristics at baseline by study group. Distribution by study group was similar for all patient characteristics, demonstrating the success of randomization.
Inhaled corticosteroids mean daily dosage at baseline was 813 pLg for alendronate (SD 698 pLg) and 789 Ftg for placebo (SD 683 Rig) (Student's t-test: P = 0.839). At baseline, the total number of booster courses of oral corticosteroids in the last two years were 3.2 courses for the alendronate group (SD 3.1 courses) and 2.8 for placebo group (SD 4.2 courses) (Student's t-test: P = 0.538). Finally, Table 2 shows a comparison of mean BMD measures at baseline by study group. For both T and Z scores, means were similar for the two study groups, without statistically significant differences.
End of trial results
Over the course of the 12 month study 24 (36%) of the alendronate group and 26 (33%) of the placebo group withdrew from the study (Exact chi-squared 
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test: P = 0.727). Of those who withdrew, main reasons included: voluntary withdrawal (38%); adverse event (36%); loss to follow up (16%); and protocol violation (10%). This pattern was similar in the two study groups (Exact chi-squared test: P = 0.979). Table 3 shows the intention to treat analysis mean change in BMD outcome measures at 12 months by study group. The difference between groups was not statistically significant. This analysis included all patients whether or not they had withdrawn from the trial, since a BMD assessment attempt was made on all patients at 12 months. Clearly those who withdrew would have had less time on active drug. Table 4 shows the per protocol analysis mean change in BMD outcome measures at 12 months by study group for those patients not withdrawing from the study. T and Z scores for the lumbar spine but not hip BMD showed a statistically significant benefit associated with alendronate, in this per protocol analysis.
The median (IQR) compliance score for the alendronate group was 0.97 (0.090) compared with 0.96 (0.095) for the placebo group. This difference was not statistically significant (Exact Mann-Whitney U-Test: P = 0.590).
Over the duration of the study, 45.4% of the alendronate group had one or more adverse events compared with 53.0% of the placebo group. The difference between the groups was not statistically significant (Fisher's Exact Test: P = 0.467).
In the alendronate group, three subjects reported new vertebral fractures, while in the control group fractures of knee, toe, foot, rib, and hip were reported in five subjects (Fisher's Exact test: P = 0.727). bn varies across columns, as T or Z scores were omitted for six patients due to results being technically unreliable (n = 95).
Discussion
We studied a group of subjects of mean age 67, with clinically significant airways disease (median FEV1% predicted <45% in both study arms) who had been found to have reduced BMD following screening of patients recruited primarily through tertiary hospital outpatient clinics, recent inpatient discharges, and through general practices. We evaluated the effect of daily alendronate treatment on BMD in this group of airways disease patients and demonstrated no benefit on intention to treat analysis. With per protocol analysis, there was an improvement in T and Z scores for lumbar spine, but not hip BMD in the alendronate group. Although this group of patients have a high prevalence and incidence of fractures, associated with reduced BMD,3 the high withdrawal rate in both the placebo arm and the alendronate arm indicates that this patient group has such a high background prevalence of comorbidities and symptomatologies, that administration of medications such as once daily alendronate may have limited practicality in some chronically ill people.
Participants had airways disease across the spectrum of asthma to COAD. Subjects were not tested for airflow obstruction reversibility, due to limited reproducibility of such reversibility testing as a basis for categorizing as asthma or COAD in a mutually exclusive way. Likely blunting of reversibility by concurrent use of medications, including inhaled corticosteroids, and a likely coexistence of both COAD and a component of asthma in many subjects, limits the utility of attempting to categorize. No subjects with cor pulmonale were excluded, as this would have excluded those with more severe airways disease from the study, and therefore limited the generalizability of our results. Arterial blood gas estimations of oxygenation were not performed, as clinical practice would not routinely dictate this when considering commencement of therapy to restore BMD of subjects who have been found to be osteopaenic.
Prescribing alendronate on a daily basis requires compliance to appropriate steps to minimize adverse events such as oesophageal perforation,18 or oesophagitis associated with the use of alendronate.18 However, our withdrawal rate was higher than reported rates from previous studies in other study groups, including postmenopausal women after one year of daily treatment (5.8% in the placebo group and 8.2% in the alendronate group).13 Studies exceeding one year also reported lower withdrawal rates (16-17% for placebo, 12 -13% in alendronate groups).13'19 Our withdrawal problem was observed despite exclusion of study Chronic Respiratory Disease volunteers with dysphagia or dyspepsia as well as those who were taking proton pump inhibitors for gastroeosophageal reflux.
Increase in hip BMD of 2.2%, and lumbar spine BMD of 3.3% over one year of alendronate treatment has been reported in subjects commencing oral corticosteroid treatment. 15 We have demonstrated small but comparable effects of alendronate in our per protocol analysis for the lumbar spine. In postmenopausal women, 3-4 years of alendronate increases hip and spine BMD by 3.0-6.2% and 6.8-8.8% and reduces the relative risk of hip and spine fractures by 21-78% and 45-49% respectively. 13'14'20 Alendronate continues to increase hip BMD for 3-5 years, and prevent bone loss for a further two years in postmenopausal women.21 Therefore BMD benefits in our study group may continue to accrue beyond the 12 month follow up of our study, with potential for demonstrable changes for hip as well as lumbar spine, provided sustained compliance for medication is achieved.
People with airways disease are at special risk of cough fractures of ribs, vertebral compression fractures and of poor outcomes following hip fractures due to their respiratory comorbidities. Although incident fractures were recorded at each of the three monthly interviews, our study was not designed to have sufficient statistical power to demonstrate differences in fracture rates. BMD was chosen as an intermediate outcome measure, given its clearly demonstrated relationship to fractures.
It should not be assumed that anti-osteoporosis treatment benefits demonstrated in studies including generally well participants can be extrapolated to elderly subjects with airways disease who may differ with respect to exercise capability, avoidance of dairy foods,3 medication compliance and tolerance.
Significant improvement in only lumbar BMD, demonstrated by per protocol but not intention to treat analysis, indicates the clinical benefits of such therapy will only be achieved with simplified patient friendly prescriptive practices. Many of our study subjects were elderly, often concurrently prescribed numerous medications, and often expressed concern regarding the consequences of taking alendronate incorrectly. To facilitate compliance, newer simplified medication approaches are likely to prove more beneficial, including weekly alendronate22 and annual intravenous zolendronate23 which need to be evaluated. Given the morbidity and mortality associated with osteoporotic hip fractures, and our failure to demonstrate any benefit at the hip at 12 months, such studies need to ensure long term evaluation of potential hip benefits. 
